How Should Chinese Women Approach Breast Cancer Screening?

How Should Chinese Women Approach Breast Cancer Screening?

2024.08.16
Breast cancer has now become the most common malignant tumor worldwide and is one of the most prevalent cancers among Chinese women, posing a serious threat to their physical and mental health. While significant progress has been made in the treatment and drug development for breast cancer, providing more targeted treatment options for different types of patients and improving survival rates and quality of life, our ultimate goal is to reduce the incidence of breast cancer through screening and prevention. Early detection is crucial for improving treatment outcomes and extending survival times. This article discusses breast cancer screening and how high-risk groups can reduce their risk of developing breast cancer.
In-Depth Analysis | Dr. Yuhua Song & Dr. Jing Yao: Treatment Options for HR+/HER2- Breast Cancer Patients After CDK4/6i Progression

In-Depth Analysis | Dr. Yuhua Song & Dr. Jing Yao: Treatment Options for HR+/HER2- Breast Cancer Patients After CDK4/6i Progression

2024.08.16
After CDK4/6i treatment failure in HR+/HER2- breast cancer patients, do you lean more towards a PI3K inhibitor or an AKT inhibitor? At the Northern Salon of the 2024 Summer Breast Cancer Forum, during the "In-Depth Analysis" segment, Dr. Yuhua Song from The Affiliated Hospital of Qingdao University and Dr. Jing Yao from Union Hospital Affiliated with Huazhong University of Science and Technology each presented their views. Professor Song expressed a preference for PI3K inhibitors, while Professor Yao favored AKT inhibitors. Following the session, Cancer Outlook invited both experts to elaborate on their perspectives.
In-Depth Analysis | Dr. Xuening Ji & Dr. Chunfang Hao: Treatment Options After TKI Therapy Failure in HER2-Positive Breast Cancer

In-Depth Analysis | Dr. Xuening Ji & Dr. Chunfang Hao: Treatment Options After TKI Therapy Failure in HER2-Positive Breast Cancer

2024.08.16
After the failure of TKI therapy in HER2-positive breast cancer, would you prefer an "ADC" or "HP+" regimen? At the Northern Salon of the 2024 Summer Breast Cancer Forum, during the "In-Depth Analysis" segment, Dr. Xuening Ji from Affiliated Zhongshan Hospital of Dalian University and Dr. Chunfang Hao from Tianjin Cancer Hospital shared their perspectives. Professor Ji advocated for the ADC approach, while Professor Hao supported the "HP+" regimen. Following the session Oncology frontier  invited both experts to elaborate on their viewpoints.
Dr. Jidong Jia: Progress and Challenges in the Prevention and Treatment of Hepatitis B in China

Dr. Jidong Jia: Progress and Challenges in the Prevention and Treatment of Hepatitis B in China

2024.08.15
China has historically been a high-prevalence area for Hepatitis B virus (HBV) infection, with a hepatitis B surface antigen (HBsAg) prevalence rate of 9.7% in 1992. Comprehensive strategies, including the hepatitis B vaccine program for newborns (HepB), with a strong emphasis on timely administration of the birth dose and completion of the three-dose schedule, have significantly reduced mother-to-child transmission and early childhood HBV infections. With the significant reduction in the cost of antiviral drugs, treatment accessibility and affordability have greatly improved. From July 20 to 21, the "2024 World Hepatitis Day Campaign and Hepatitis Elimination Action Conference" was held in Beijing. Dr. Jidong Jia from Beijing Friendship Hospital ,Capital Medical University delivered a keynote speech titled "Progress and Challenges in the Prevention and Treatment of Hepatitis B in China," where he systematically explained the progress made, the challenges faced, and the urgent actions needed in the prevention and treatment of hepatitis B in China.
Expert Commentary | Dr. Lin Zhang: Immune Activation as the Foundation for Sustained Efficacy of Yttrium-90 Radioembolization in Liver Cancer

Expert Commentary | Dr. Lin Zhang: Immune Activation as the Foundation for Sustained Efficacy of Yttrium-90 Radioembolization in Liver Cancer

2024.08.15
Yttrium-90 (Y90) resin microsphere selective internal radiotherapy (Y90-RE) is a minimally invasive local treatment method that can effectively control tumor progression in hepatocellular carcinoma (HCC) patients who are ineligible for resection or ablation, with compensated liver function and good overall condition. With the advancement of precision medicine, the clinical understanding of immune activation by Y90-RE has deepened, revealing the potential of pre-Y90-RE peripheral blood mononuclear cell (PBMC) immune profiling in predicting patient prognosis. Hepatology Digest invited Dr. Lin Zhang from Beijing Tsinghua Changgung Hospital to interpret a study published in Gut (IF=23), which explores the immune activation mechanisms of Y90-RE.
SIFIC Insights: “The Essential Growth Path for Infection Control Professionals” & “Supporting the Future of China’s Infection Control Field”

SIFIC Insights: “The Essential Growth Path for Infection Control Professionals” & “Supporting the Future of China’s Infection Control Field”

2024.08.15
The 20th Shanghai International Forum for Infection Control (SIFIC), in conjunction with the 8th Oriental Forum on Challenging Infectious Diseases (OFCID) and the Academic Corference of Global Chinese Association of Clinical Microbiology & Infectious Diseases (SIFIC 2024 "National Infection Control and Challenging Infectious Diseases" Combined Conference), was grandly inaugurated in Shanghai. "Xiaoshi," a reporter from Infection Medical Line, interviewed some of the participants at the SIFIC event, sharing the growth journey and bright future of SIFIC.
Precision Diagnosis and Control: SIFIC’s milestone conference for 20 years opens, drawing a new blueprint for infection control

Precision Diagnosis and Control: SIFIC’s milestone conference for 20 years opens, drawing a new blueprint for infection control

2024.08.15
On July 26, 2024, the highly anticipated 20th Shanghai International Forum for Infection Control (SIFIC), in conjunction with the 8th Oriental Forum on Complex Infectious Diseases (OFCID) and the Annual Meeting of the Global Chinese Society of Clinical Microbiology and Infectious Diseases, was grandly inaugurated at the Shanghai International Conference Center. Themed "Precision Diagnosis, Precision Control," this year's conference aims to enhance the scientific and precise approach to infection prevention and control in China. Marking SIFIC's 20th anniversary, the conference not only reflected on past achievements but also looked forward to the boundless possibilities in the field of infection control, inspiring every participant to move forward together in writing a new chapter for infection prevention and control.
Emerging Perspectives: July Literature Digest (Part 2)

Emerging Perspectives: July Literature Digest (Part 2)

2024.08.15
In today’s information overload era, how can one stay updated on the latest advancements in the field? Here, we curate the most recent literature each month, focusing on hot topics and offering a comprehensive analysis of the latest developments in hematologic diseases. Join us as we track the latest trends, gain insights into scientific research, and explore the limitless possibilities in the world of hematology. Stay tuned—don’t miss our monthly updates!
Dr. Huilai Zhang: Current Status and Treatment Progress for Chinese Patients with Marginal Zone Lymphoma 🌟 | The 8th CSCO Hematology Academic Conference—Considerations for the Application of Chemotherapy-Free Regimens

Dr. Huilai Zhang: Current Status and Treatment Progress for Chinese Patients with Marginal Zone Lymphoma 🌟 | The 8th CSCO Hematology Academic Conference—Considerations for the Application of Chemotherapy-Free Regimens

2024.08.15
Marginal zone lymphoma (MZL), a group of indolent mature B-cell lymphomas, presents a significant challenge in treatment selection due to its high heterogeneity. Despite improvements in survival rates for MZL patients with the advent of new drugs and advancements in clinical diagnostic and therapeutic techniques, developing a balanced management plan that addresses both efficacy and safety across a long disease course and lifetime management remains an urgent issue. At the recent "8th Academic Conference on Hematologic Oncology" organized by the Chinese Society of Clinical Oncology (CSCO), Dr. Huilai Zhang from Tianjin Medical University Cancer Institute & Hospital delivered a compelling presentation titled "Current Status and Treatment Progress for Chinese Patients with Marginal Zone Lymphoma." This report offers valuable insights and forward-looking guidance for comprehensively understanding the current state of MZL diagnosis and treatment in China and mastering the latest developments in the field. This article summarizes the key points of Professor Zhang's presentation for our readers.
ASCOBT24 | Efficacy and Patient-Reported Outcomes of Enfortumab Vedotin Combined with Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

ASCOBT24 | Efficacy and Patient-Reported Outcomes of Enfortumab Vedotin Combined with Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

2024.08.15
For many years, platinum-based chemotherapy has been the standard treatment for metastatic urothelial carcinoma. However, this year’s EV-302/KEYNOTE-A39 study results, published in the New England Journal of Medicine (NEJM), demonstrated that the combination of enfortumab vedotin and pembrolizumab (EV+P) significantly improves survival outcomes for patients with locally advanced or metastatic urothelial carcinoma. The 2024 ASCO Breakthrough conference, held from August 8-10 in Yokohama, Japan, presented the efficacy and patient-reported outcomes (PROs) from the KEYNOTE-A39 study. Here is a summary for our readers.